Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17767297 | 0.81 | MRGPRX4 (0.47) | MRGPRX4PTGDR2MAOBRXRARXRB | |
| SCHEMBL16335644 | 0.80 | IDO1 (0.39) | MRGPRX4CYP4F2CYP4A11IDO1PTGDR2 | |
| SCHEMBL16335177 | 0.80 | MRGPRX4 (0.43) | MRGPRX4PTGDR2MAOBRXRARXRB | |
| SCHEMBL17767298 | 0.80 | MRGPRX4 (0.46) | MRGPRX4PTGDR2MAOBRXRARXRB | |
| SCHEMBL13321691 | 0.73 | MAOB (0.60) | MRGPRX4IDO1MAOBRXRARXRB | |
| SCHEMBL18003069 | 0.72 | IDO1 (0.51) | IDO1PTGDR2MAOBMAOASLC6A4 | |
| SCHEMBL21945019 | 0.71 | IDO1 (0.55) | MRGPRX4IDO1PTGDR2MAOBSLC6A4 | |
| SCHEMBL11790248 | 0.70 | TSHR (0.44) | TDP1 | |
| SCHEMBL21944901 | 0.70 | IDO1 (0.56) | MRGPRX4IDO1PTGDR2MAOBSLC6A4 | |
| SCHEMBL21944807 | 0.69 | MRGPRX4 (0.65) | MRGPRX4CYP4F2CYP4A11MAOBRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| EP-3013794-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014207071-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | DPM1, CROCC, SNX1 | MRGPRX4 2298/4885CYP4F2 4347/4885CYP4A11 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.